Healthcare stocks drop after Obamacare ruling

Amy Baxter | | Health Exec | Policy & Regulations
Stocks

Healthcare stocks were jolted after news of a Texas judge’s ruling that the Affordable Care Act was unconstitutional, with hospital and insurance stocks among the worst performers of a selloff on Dec. 17, Bloomberg reported.

The ruling, which was handed down on Dec. 14, overturns the ACA. It has thrown the future of the healthcare system into flux, though the healthcare law will remain in place while the case faces an appeals process.

U.S. hospitals fell 4.4 percent on Monday, the lowest level since March 1, according to Bloomberg. Elsewhere, the S&P 500 Managed Care Index dropped 2.3 percent, while Molina dipped as much as 13.5 percent. Molina and Centene are currently facing the biggest losses on the market due to their high exposures to Medicaid and Obamacare markets.

See the full story below:

Hospitals, Insurers Sink as Obamacare Ruling Jolts Investors

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

Mangione now faces federal charges, death penalty in murder of UHC CEO
FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
DOJ sues CVS over unlawful opioid prescriptions and reimbursement
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders
Advancing AI for vascular surgery will require a commitment to data integrity

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.